Kardigan targets IPO to support cardiology pipeline progression

▤ Summary

Kardigan is preparing to go public on Nasdaq under the ticker KARD. The company wants to use IPO proceeds to advance three in-licensed cardiology therapies through clinical development. Its lead assets include danicamtiv for genetic dilated cardiomyopathy, ataciguat for moderate calcific aortic valve stenosis, and tonlamarsen for severe hypertension. Kardigan also plans to use any remaining capital for acquisitions, in-licensing, or investments tied to its core heart-health focus. The move follows a $254 million Series B round raised in late 2025.

$ Funding

▦ Linked Companies